Chemi-Verse™ RSK4 Kinase Assay Kit

Catalog #
82523
$535 *
Size: 96 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The Chemi-Verse™ RSK4 Kinase Assay Kit is designed to measure RSK4 (ribosomal S6 kinase 4) kinase activity for screening and profiling applications using ADP-Glo™ as a detection reagent. The assay kit comes in a convenient 96-well format, with enough recombinant purified RSK4, kinase substrate, ATP, and kinase assay buffer for 100 enzyme reactions.

Need us to run inhibitor screens or profile your compounds against RSK4? Check out our Kinase Screening and Profiling Service.

Synonyms
Ribosomal protein S6 kinase alpha-6, S6K-alpha-6, 90 kDa ribosomal protein S6 kinase 6, p90-RSK 6, p90RSK6, Ribosomal S6 kinase 4, RSK4, RSK-4, pp90RSK4
Product Info
Storage and Usage
Citations
Assay Kit Format
Luminescent
Materials Required But Not Supplied
  • ADP-Glo™ Kinase Assay (Promega #V6930)
  • DTT (Dithiothreitol), 1M, optional
  • Microplate reader capable of reading luminescence
  • Adjustable micropipettor and sterile tips
  • 30°C incubator
Format
Catalog # Name Amount Storage
  RSK4* 2 µg -80°C
79334 5x Kinase Buffer 1 1.5 ml -20°C
79686 500 µM ATP 50 µl -20°C
  RSK Substrate (5 mg/ml) 100 µl -20°C
79696 White 96-well plate 1 Room Temp

*The concentration of the protein is lot-specific and will be indicated on the tube.

UniProt #
Q9UK32
Background

RSK4 (ribosomal S6 kinase 4) is a member of the serine/threonine RSK family of proteins. In vertebrates this family has four isoforms, RSK1-4, involved in cell growth, proliferation, motility, and apoptosis, acting as downstream effectors of the Ras/ERK (extracellular signal regulated kinase) pathway. RSK4 is found at high levels in the kidney, the brain, and the thyroid gland. It is linked to ESCC (esophageal squamous cell carcinoma) where it is found at high levels and phosphorylates GSK-3β to activate the β-catenin signaling pathway and leads to resistance to radiotherapy. Inhibition of this protein with the inhibitor BI-D1870 was able to increase the sensitivity of the ESCC cells to radiotherapy in animal models. In glioblastoma RSK4 phosphorylates EZH2 (enhancer of zeste homolog 2) and contributes to resistance to treatment with EZH2 inhibitors. RSK4 contributes to treatment resistance and cancer progression in kidney carcinoma, melanoma and RCC (renal cell carcinoma) cell lines, but the role of RSK4 as a tumor suppressor or oncogene may be cancer dependent and remains controversial. A deeper understanding of the role of this protein in cancer combined with the use of inhibitors alone or in combinatory therapy may prove a new therapeutic avenue in cancer therapy.

References

Li M.-Y., et al., 2020 J Clin Invest 130 (8) : 4301-4319.
Pang F., et al., 2023 Cancer Gene Ther. 30(12) :1636-1648.